إعلان
إعلان
XLO
Xilio Therapeutics, Inc. Common Stock
0.73
USDبرعاية
+0.02
+2.95%
٠٨ يناير, ١٥:٥٨ UTC -5
مغلق
بعد الإغلاق
0.73
0.00
0.00%
تقارير أرباح XLO
النسبة الإيجابية المفاجئة
XLO تفوق 10 من 17 آخر التقديرات.
59%
التقرير التالي
بيانات التقرير القادم
٠٩ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$8.04M
/-$0.12
التغير الضمني من Q3 25 (Revenue/ EPS)
-57.83%
/--
التغير الضمني من Q4 24 (Revenue/ EPS)
+366.33%
/-40.00%
Xilio Therapeutics, Inc. Common Stock earnings per share and revenue
On ١٣ نوفمبر ٢٠٢٥, XLO reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.03 USD, resulting in a 80.20% surprise. Revenue reached 19.07 مليون, compared to an expected 18.82 مليون, with a 1.30% difference. The market reacted with a -9.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 2 المحللين forecast an EPS of -0.12 USD, with revenue projected to reach 8.04 مليون USD, implying an -- of --% EPS, and نقصان of -57.83% in Revenue from the last quarter.
الأسئلة الشائعة
What were Xilio Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Xilio Therapeutics, Inc. Common Stock reported EPS of $0.00, beating estimates by 80.2%, and revenue of $19.07M, 1.3% above expectations.
How did the market react to Xilio Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -9.28%, changed from $0.77 before the earnings release to $0.70 the day after.
When is Xilio Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٠٩ مارس ٢٠٢٦.
What are the forecasts for Xilio Therapeutics, Inc. Common Stock's next earnings report?
Based on 2
المحللين, Xilio Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $8.04M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان